Epizyme, Inc. is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment. Epizyme has two programs in clinical development. Our lead program, EPZ-6438, is in Phase 1/2 development for Non-Hodgkin Lymphoma and a subset of genetically defined tumors including malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas. Epizyme owns worldwide rights to EPZ-6438 outside of Japan, and plans to start a broad Phase 2 clinical development program in 2015. Epizyme‘s management team, scientific advisors, and board of directors are recognized leaders in the scientific community and biopharmaceutical industry. Working together, we are committed to developing novel epigenetic therapeutics for cancer patients. Epizyme is headquartered in Cambridge, MA.
Company Growth (employees)
Key People at Epizyme
Robert A. Copeland
Epizyme Office Locations
Epizyme Data and Metrics
Epizyme Financial Metrics
Revenue (FY, 2016) | 8 m |
Revenue growth (FY, 2015 - FY, 2016), % | 213% |
Net income (FY, 2016) | (110.2 m) |
EBIT (FY, 2016) | (111.8 m) |
Market capitalization (23-Jun-2017) | 857.9 m |
Closing share price (23-Jun-2017) | 13.7 |
Cash (31-Dec-2016) | 77.9 m |
| $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 68.5 m | 41.4 m | 2.6 m | 8 m |
Revenue growth, % | (40%) | (94%) | 213% | |
Operating expense total | 71.6 m | 96.5 m | 135.1 m | 119.8 m |
EBIT | (3.1 m) | (55.1 m) | (132.5 m) | (111.8 m) |
EBIT margin, % | (5%) | (133%) | (5178%) | (1397%) |
Interest income | 74 k | 95 k | ||
Pre tax profit | (3.1 m) | (54.9 m) | (132.4 m) | (110.2 m) |
Income tax expense | 349 k | 109 k | ||
Net Income | (3.5 m) | (55 m) | (132.4 m) | (110.2 m) |
| $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 123.6 m | 190.1 m | 208.3 m | 77.9 m |
Accounts Receivable | 33.7 m | 2.1 m | 262 k | 23 k |
Inventories | 2.4 m | 2.8 m | 4.5 m | 6.5 m |
Current Assets | 159.7 m | 195 m | 213.1 m | 248.7 m |
PP&E | 2.2 m | 3.6 m | 4.1 m | 3.1 m |
Total Assets | 163 m | 199.2 m | 217.9 m | 252.4 m |
Accounts Payable | 4.7 m | 8.3 m | 4.7 m | 5 m |
Current Liabilities | 34.6 m | 17 m | 18.4 m | 21.6 m |
Additional Paid-in Capital | 160.4 m | 271.4 m | 413 m | 555.5 m |
Retained Earnings | (56.1 m) | (111.1 m) | (243.5 m) | (353.7 m) |
Total Equity | 104.3 m | 160.3 m | 169.5 m | 201.7 m |
Financial Leverage | 1.6 x | 1.2 x | 1.3 x | 1.3 x |
| $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (3.5 m) | (55 m) | (132.4 m) | (110.2 m) |
Depreciation and Amortization | 703 k | 742 k | 1.4 m | 1.6 m |
Accounts Receivable | (32 m) | 31.6 m | 1.8 m | 239 k |
Inventories | (1.5 m) | (419 k) | (1.6 m) | (1.5 m) |
Accounts Payable | 1.6 m | 3.6 m | (3.6 m) | 341 k |
Cash From Operating Activities | (53.7 m) | (35.4 m) | (72.9 m) | (96.4 m) |
Purchases of PP&E | (630 k) | (2.2 m) | (183 k) | (624 k) |
Cash From Investing Activities | (630 k) | (2.2 m) | (40.2 m) | (165.4 m) |
Cash From Financing Activities | 79.9 m | 104.1 m | 131.3 m | 131.4 m |
Income Taxes Paid | 963 k | 963 k | 963 k |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.3 x |
